{
    "nctId": "NCT06078670",
    "briefTitle": "PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors",
    "officialTitle": "Phase Ib/II Clinical Study of PARP Inhibitor CVL218 in Combination With Therapy in Patients With Advanced Solid Tumors",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Advanced Solid Tumor",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 96,
    "primaryOutcomeMeasure": "Incidence of dose-limiting toxicity (DLT) during the observation period of DLT",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* 1. Patients between the ages of 18 and 75 (including those aged 18 and 75, and those over 60 years old should not suffer from more than 3 complications of heart, lung, liver and kidney function at the same time), regardless of gender.\n\n  2. Patients with locally advanced or metastatic advanced solid tumors confirmed by histology or cytology (including but not limited to triple-negative breast cancer, gastric cancer, colorectal cancer); Patients with \u22641 line of standard treatment failure (disease progression after treatment or intolerability of toxic side effects of treatment), or no standard treatment, or unable to receive standard treatment.\n\n  3. In stage II, patients with positive PD-L1 molecular expression level combined with CPS\u22651 were required to be enrolled, or there was evidence of harmful HRD gene variants (BRCA1, BRCA2, PALB2, ATM, CHEK2 variants, etc.).\n\nExclusion Criteria:\n\n* Chemotherapy, radiotherapy, biotherapy and endocrinology were received within 4 weeks before the first administration\n\nTreatment, immunotherapy and other antitumor drugs, except the following:\n\nNitrosourea or mitomycin C within 6 weeks before first use of the study drug;\n\nOral fluorouracil and small molecule targeted drugs are used before first investigational drugs\n\n2 weeks or within 5 half-lives of the drug, whichever is longer;\n\nTraditional Chinese medicines with anti-tumor indications were used within 2 weeks before the first use of study drugs.\n\n2. Received other investigational drugs or treatments that are not on the market within 4 weeks prior to initial administration\n\nTherapy.\n\n3. Received major organ surgery (excluding puncture) within 4 weeks prior to initial administration\n\nBiopsy) or significant trauma.\n\n4. Received systemic glucocorticoids (strong) within 14 days prior to initial administration\n\nPine \\> 10mg/ day or equivalent dose of similar drugs) or other immunosuppressant\n\nTreatment;\n\nExcept in the following cases: topical, ocular, intraarticular, intranasal, and inhalation\n\nType I glucocorticoid therapy; Short-term use of corticosteroids for prophylactic treatment (eg to prevent contrast allergy).",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}